JP2014521070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521070A5 JP2014521070A5 JP2014519031A JP2014519031A JP2014521070A5 JP 2014521070 A5 JP2014521070 A5 JP 2014521070A5 JP 2014519031 A JP2014519031 A JP 2014519031A JP 2014519031 A JP2014519031 A JP 2014519031A JP 2014521070 A5 JP2014521070 A5 JP 2014521070A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- ang2
- plgf concentration
- binding polypeptide
- sorafenib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502686P | 2011-06-29 | 2011-06-29 | |
| US61/502,686 | 2011-06-29 | ||
| PCT/US2012/044673 WO2013003606A1 (en) | 2011-06-29 | 2012-06-28 | Predictive biomarker of survival in the treatment of renal cell carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014521070A JP2014521070A (ja) | 2014-08-25 |
| JP2014521070A5 true JP2014521070A5 (https=) | 2015-08-13 |
| JP6069312B2 JP6069312B2 (ja) | 2017-02-01 |
Family
ID=46545468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519031A Active JP6069312B2 (ja) | 2011-06-29 | 2012-06-28 | 腎細胞癌の治療における生存の予測バイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9151761B2 (https=) |
| EP (1) | EP2726088B1 (https=) |
| JP (1) | JP6069312B2 (https=) |
| AU (1) | AU2012275346B2 (https=) |
| CA (1) | CA2840212A1 (https=) |
| MX (1) | MX358726B (https=) |
| WO (1) | WO2013003606A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| AU2015345323A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| CA2963606A1 (en) * | 2014-11-10 | 2016-05-19 | F.Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| WO2016209972A1 (en) * | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| WO2017110764A1 (ja) * | 2015-12-24 | 2017-06-29 | 公益財団法人がん研究会 | マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー |
| JP6942135B2 (ja) * | 2016-01-25 | 2021-09-29 | サノフイＳａｎｏｆｉ | 血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US5871723A (en) | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
| US6248327B1 (en) | 1998-09-11 | 2001-06-19 | Vanderbilt University | Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| CA2633211A1 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| EP2089425B1 (en) | 2006-11-10 | 2011-08-17 | CovX Technologies Ireland Limited | Anti-angiogenic compounds |
| WO2008115714A2 (en) * | 2007-03-20 | 2008-09-25 | Apocell, Inc. | Evaluating rtk target drugs |
| EP2288383A1 (en) * | 2008-05-14 | 2011-03-02 | Amgen, Inc | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
-
2012
- 2012-06-28 MX MX2013015146A patent/MX358726B/es active IP Right Grant
- 2012-06-28 US US14/127,157 patent/US9151761B2/en active Active
- 2012-06-28 EP EP12737394.2A patent/EP2726088B1/en active Active
- 2012-06-28 JP JP2014519031A patent/JP6069312B2/ja active Active
- 2012-06-28 AU AU2012275346A patent/AU2012275346B2/en active Active
- 2012-06-28 CA CA2840212A patent/CA2840212A1/en not_active Abandoned
- 2012-06-28 WO PCT/US2012/044673 patent/WO2013003606A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521070A5 (https=) | ||
| Chen et al. | Angiopoietin‐like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma | |
| Gavalas et al. | Angiogenesis-related pathways in the pathogenesis of ovarian cancer | |
| JP6630397B2 (ja) | アデノウイルスを用いた治療方法 | |
| JP6122776B2 (ja) | 腫瘍細胞由来微小胞 | |
| Kordbacheh et al. | Current and emerging molecular therapies for head and neck squamous cell carcinoma | |
| Herrera et al. | A snapshot of the tumor microenvironment in colorectal cancer: the liquid biopsy | |
| PH12019500440A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| EA201000785A1 (ru) | Композиции для доставки в легкие | |
| Műzes et al. | Cell-free DNA in the pathogenesis and therapy of non-infectious inflammations and tumors | |
| JP2015511964A5 (https=) | ||
| Yao et al. | Unveiling the role of HGF/c-Met signaling in non-small cell lung cancer tumor microenvironment | |
| Liang et al. | Sevoflurane attenuates platelets activation of patients undergoing lung cancer surgery and suppresses platelets-induced invasion of lung cancer cells | |
| PH12012500826A1 (en) | Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
| Rao et al. | Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer | |
| Chen et al. | CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells | |
| EP3216460B1 (en) | Antigen polypeptide for detecting plasma immunological marker-vegfr1 autoantibody and use thereof | |
| Chen et al. | Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma | |
| Ma et al. | cGAS suppresses hepatocellular carcinoma independent of its cGAMP synthase activity | |
| Dai et al. | Mechanisms of Immune Checkpoint Inhibitor Resistance in Hepatocellular Carcinoma and Strategies for Reversal | |
| JP2012524248A5 (https=) | ||
| Toffanin et al. | Next-generation sequencing: path for driver discovery in hepatocellular carcinoma | |
| Lei et al. | Pathogenesis and systemic treatment of hepatocellular carcinoma: current status and prospects | |
| JP2016535266A5 (https=) | ||
| JP2012127879A (ja) | 腎症の進行度の判定方法並びに線維化抑制剤。 |